Abstract: This invention relates to the preparation of N-(phosphonomethyl)glycine (“glyphosate”) from N-(phosphonomethyl)iminodiacetic acid (“PMIDA”), and more particularly to methods for control of the conversion of PMIDA, for the identification of reaction end points relating to PMIDA conversion and the preparation of glyphosate products having controlled PMIDA content.

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The present invention relates to the use of proline for reducing the viscosity of a protein preparation.

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The present invention relates to the use of proline for reducing the viscosity of a protein preparation.

Abstract: The present invention relates to the use of proline for reducing the viscosity of a protein preparation.

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The present invention relates to the use of proline for reducing the viscosity of a protein preparation.

Abstract: The present invention relates to the use of proline for reducing the viscosity of a protein preparation.

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The present invention relates to the use of proline for reducing the viscosity of a protein preparation.

Abstract: A safety device for a stored-program control includes a controller which exchanges data with a stored-program control and, via a bus controller and a bus system, with the peripheral to be controlled. A memory is provided, in which safety-relevant data of the stored-program control is stored, which is accessible to the controller.

Abstract: The invention relates to the use of reconstituted HDL for improving the endothelial function in patients suffering from hypercholesterolaemia and for treating or preventing acute coronary diseases such as unstable angina pectoris.

Abstract: The invention relates to the use of reconstituted HDL for improving the endothelial function in patients suffering from hypercholesterolaemia and for treating or preventing acute coronary diseases such as unstable angina pectoris.

Abstract: Reconstituted high density lipoproteins (rHDL) are produced from apolipoproteins and lipids in that an aqueous apolipoprotein solution with a concentration of 1-40 g protein/l is mixed with an aqueous lipid-detergent solution without mandatory addition of organic solvents, the molar ratio of lipid to detergent being 1:0.5 to 1:4 and the weight ratio of lipid to detergent being 1:1.5 to 1:5, the resultant apolipoprotein-lipid-detergent mixture then being incubated at a temperature in the range of the phase change temperature of the lipid in water .+-.10.degree. C., and the detergent being at least partially removed.The rHDL are useful for various prophylactic and therapeutic treatments of diseases that have a connection with lipids and lipidoidal substances. This method is especially suitable for technical and industrial production.

Abstract: An anti-D immunoglobulin G-preparation is produced in high-yield from human plasma containing anti-D IgG, or a plasma fraction containing an anti-D IgG, in which (A) the plasma, or the plasma fraction, with a pH in the range of pH 3.5 to 6.5 and a conductivity value in the range of 2 to 4 mS/cm, is subjected to ion exchange chromatography with an adsorbent which has carboxymethyl groups as functional groups, the anti-D IgG being bound to the adsorbent, (B) the adsorbent with the bound anti-D IgG is first rinsed with a wash solution at a pH in the range of 5 to 8 and a conductivity value in the range of 2 to 4 mS/cm, and the anti-D IgG is subsequently eluted, and further (C) the eluted anti-D IgG at a pH in the range of 6 to 8 and a conductivity value in the range of 2 to 4 mS/cm is treated with an alkaline adsorbent with ion-exchange characteristics in order to bind undesired components, and finally, the anti-D IgG is concentrated.